Literature DB >> 821969

Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis.

L A Harker, R Ross, S J Slichter, C R Scott.   

Abstract

The atherogenic mechanism of homocystinemia has been defined by measuring endothelial cell loss and regeneration, platelet consumption, and intimal lesion formation in a primate model. Three groups of baboons were studied: (a) 8 control animals; (b) 15 animals after 3 mo of continuous homocystinemia; and (c) 11 animals after 3 mo of combined homocystinemia and oral treatment with dipyridamole. Experimental homocystinemia caused patchy endothelial desquamation comprising about 10% of the aortic surface despite a 25-fold increase in endothelial cell regeneration. Neither endothelial cell loss nor regeneration was changed significantly by dipyridamole. Homocystine-induced vascular deendothelialization produced a threefold increase in platelet consumption that was interrupted by dipyridamole inhibition of platelet function. All homocystinemic animals developed typical arteriosclerotic or preatherosclerotic intimal lesions composed of proliferating smooth muscle cells averaging 10-15 cell layers surrounded by large amounts of collagen, elastic fibers, glycosaminoglycans, and sometimes lipid. Intimal lesion formation was prevented by dipyridamole therapy. We conclude that homocystine-induced endothelial cell injury resulted in arteriosclerosis through platelet-mediated intimal proliferation of smooth muscle cells that can be prevented by drug-induced platelet dysfunction.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 821969      PMCID: PMC333232          DOI: 10.1172/JCI108520

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  HOMOCYSTINURIA: A NEW INBORN ERROR OF METABOLISM ASSOCIATED WITH MENTAL DEFICIENCY.

Authors:  N A CARSON; D C CUSWORTH; C E DENT; C M FIELD; D W NEILL; R G WESTALL
Journal:  Arch Dis Child       Date:  1963-10       Impact factor: 3.791

2.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

3.  EFFECT OF ADENOSINE NUCLEOTIDES ON PLATELET AGGREGATION AND CLOTTING TIME.

Authors:  J F MUSTARD; B HEGARDT; H C ROWSELL; R L MACMILLAN
Journal:  J Lab Clin Med       Date:  1964-10

4.  HOMOCYSTINURIA: CLINICAL AND PATHOLOGICAL REVIEW OF TEN CASES.

Authors:  N A CARSON; C E DENT; C M FIELD; G E GAULL
Journal:  J Pediatr       Date:  1965-03       Impact factor: 4.406

5.  HOMOCYSTINURIA. STUDIES OF 20 FAMILIES WITH 38 AFFECTED MEMBERS.

Authors:  R N SCHIMKE; V A MCKUSICK; T HUANG; A D POLLACK
Journal:  JAMA       Date:  1965-08-30       Impact factor: 56.272

6.  I. Studies on the determination of fibrinogen in human blood plasma. II. Studies on the trypsin and plasmin inhibitors in human blood serum.

Authors:  K JACOBSSON
Journal:  Scand J Clin Lab Invest       Date:  1955       Impact factor: 1.713

7.  The regeneration of aortic endothelium.

Authors:  J C POOLE; A G SANDERS; H W FLOREY
Journal:  J Pathol Bacteriol       Date:  1958-01

8.  A basic fuchsin and alkalinized methylene blue rapid stain for epoxy-embedded tissue.

Authors:  J D Huber; F Parker; G F Odland
Journal:  Stain Technol       Date:  1968-03

9.  HOMOCYSTINURIA: ABSENCE OF CYSTATHIONINE IN THE BRAIN.

Authors:  T GERRITSEN; H A WAISMAN
Journal:  Science       Date:  1964-08-07       Impact factor: 47.728

10.  PATHOLOGICAL FINDINGS IN HOMOCYSTINURIA.

Authors:  J B GIBSON; N A CARSON; D W NEILL
Journal:  J Clin Pathol       Date:  1964-07       Impact factor: 3.411

View more
  119 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 3.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Hyperhomocysteinemia in patients with Behçet's disease: is it due to inflammation or therapy?

Authors:  Zeki Yesilova; Salih Pay; Cagatay Oktenli; Ugur Musabak; Kenan Saglam; S Yavuz Sanisoglu; Kemal Dagalp; M Kemal Erbil; Ismail H Kocar
Journal:  Rheumatol Int       Date:  2004-04-01       Impact factor: 2.631

Review 5.  Hyperhomocysteinaemia and associated disease.

Authors:  R C Bakker; D P Brandjes
Journal:  Pharm World Sci       Date:  1997-06

6.  The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease.

Authors:  J B Ubbink; W J Vermaak; J M Bennett; P J Becker; D A van Staden; S Bissbort
Journal:  Klin Wochenschr       Date:  1991-08-16

Review 7.  Nutrient supplements and cardiovascular disease: a heartbreaking story.

Authors:  Alice H Lichtenstein
Journal:  J Lipid Res       Date:  2008-11-06       Impact factor: 5.922

8.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.

Authors:  M Watanabe; J Osada; Y Aratani; K Kluckman; R Reddick; M R Malinow; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  The association of MTHFR C677T gene variants and lipid profiles or body mass index in patients with diabetic and nondiabetic coronary heart disease.

Authors:  Ozlem Kucukhuseyin; Ozlem Kurnaz; A Basak Akadam-Teker; Turgay Isbir; Zehra Bugra; Oguz Ozturk; Hulya Yilmaz-Aydogan
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

10.  Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.

Authors:  S J Sollott; L Cheng; R R Pauly; G M Jenkins; R E Monticone; M Kuzuya; J P Froehlich; M T Crow; E G Lakatta; E K Rowinsky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.